Dimitrios Schizas, Aikaterini Mastoraki, Leon Naar, Diamantis I. Tsilimigras*, Ioannis Katsaros, Vasiliki Fragkiadaki, Georgia-Sofia Karachaliou, Nikolaos Arkadopoulos, Theodore Liakakos and Dimitrios Moris Pages 6099 - 6111 ( 13 )
Chemotherapy resistance is a rising concern in Gastric Cancer (GC) and has led to the investigation of various cellular compounds. Α functional equilibrium of histone acetylation and deacetylation was discovered in all cells, regulated by Histone Acetyltransferases and Deacetylases (HDACs), controlling chromatin coiling status and changing gene expression appropriately. In accordance with recent research, this equilibrium can be dysregulated in cancer cells aiding in the process of carcinogenesis and tumor progression by altering histone and non-histone proteins affecting gene expression, cell cycle control, differentiation, and apoptosis in various malignancies. In addition, increased HDAC expression in GC cells has been associated with increased stage, tumor invasion, nodal metastases, increased distant metastatic potential, and decreased overall survival. HDAC inhibitors could be used as treatment regimens for GC patients and could develop important synergistic interactions with chemotherapy drugs. The aim of this article is to review the molecular identity and mechanism of action of HDAC inhibitors, as well as highlight their potential utility as anti-cancer agents in GC.
HDACs, gastric cancer, biochemical identity, chemotherapy resistance, multi-disciplinary approach, drug discovery.
First Department of Surgery, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Fourth Department of Surgery, National and Kapodistrian University of Athens, Attikon University Hospital, Athens, Fourth Department of Surgery, National and Kapodistrian University of Athens, Attikon University Hospital, Athens, Department of Surgery, Division of Surgical Oncology, The Ohio State University Wexner Medical Center and James Cancer Hospital and Solove Research Institute, Columbus, Ohio, First Department of Surgery, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Department of Nuclear Medicine, Evaggelismos General Hospital, Athens, Department of Medicine, Division of Hematology/Oncology, University of North Carolina, Chapel Hill, North Carolina, Fourth Department of Surgery, National and Kapodistrian University of Athens, Attikon University Hospital, Athens, First Department of Surgery, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Department of Surgery, Duke University Medical Center, Durham, North Carolina